HC Wainwright Reiterates Buy Rating for VYNE Therapeutics (NASDAQ:VYNE)

VYNE Therapeutics (NASDAQ:VYNE)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research report issued on Monday,Benzinga reports. They currently have a $5.75 price objective on the stock. HC Wainwright’s target price would indicate a potential upside of 34.35% from the company’s current price.

Separately, BTIG Research initiated coverage on shares of VYNE Therapeutics in a report on Monday, November 18th. They set a “buy” rating and a $8.00 price target on the stock.

VYNE Therapeutics Stock Up 7.0 %

NASDAQ:VYNE opened at $4.28 on Monday. The stock has a fifty day simple moving average of $2.92 and a 200 day simple moving average of $2.29. The firm has a market capitalization of $63.13 million, a price-to-earnings ratio of -4.98 and a beta of 1.30. VYNE Therapeutics has a 1-year low of $1.57 and a 1-year high of $4.29.

Institutional Investors Weigh In On VYNE Therapeutics

An institutional investor recently bought a new position in VYNE Therapeutics stock. Lynx1 Capital Management LP purchased a new position in VYNE Therapeutics Inc. (NASDAQ:VYNE) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 16,194 shares of the company’s stock, valued at approximately $32,000. VYNE Therapeutics makes up about 0.0% of Lynx1 Capital Management LP’s investment portfolio, making the stock its 17th biggest holding. Lynx1 Capital Management LP owned 0.11% of VYNE Therapeutics as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 83.78% of the company’s stock.

About VYNE Therapeutics

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.